氨酸A
Jinfeng Zhang1,2, Dandan Feng1,2, Jianjun Cheng1,2
1iHuman Institute, ShanghaiTech University, Shanghai 201210, China.
Journal of the American Chemical Society
|June 5, 2023
概括
-19核磁共振 (19F-NMR) 光谱为选G蛋白合受体 (GPCR) 配体提供了一种新方法. 使用新型探针分子的这种方法为发现向A2A腺受体 (A2AAR) 的新药候选提供了强大的替代方案.
科学领域:
- 医学化学
- 生物物理
- 药理学
背景情况:
- 传统上,G蛋白结合受体 (GPCR) 配体结合亲和力是使用放射性配体竞争试验来测量的.
- 19F核磁共振 (19F-NMR) 光谱是一种新兴的小分子化合物查技术.
- 现有的测量连体结合亲和度和选化合物的方法通常涉及不同的实验条件.
研究的目的:
- 开发和验证含的探针分子FPPA,用于与A2A腺受体 (A2AAR) 的结合研究.
- 为药物查和 afinity 测量建立一个强大的 1D 19F-NMR 协议.
- 证明 19F-NMR 与 FPPA 在发现新型 A2AAR 向药物的有用性.
主要方法:
- 基于A2AAR-V-2006复合物的含探头分子 (FPPA) 的结构设计.
- 对1D 19F-NMR测量的实验条件的开发.
- 使用已知的A2AAR配体验证基于FPPA的19F-NMR协议.
主要成果:
- 一种含的新型探针分子FPPA成功设计用于A2AAR结合研究.
- 使用FPPA进行了验证的1D 19F-NMR方案,用于药物查和亲和度测量.
- 该方法在识别已知的A2AAR配体方面表现出强大.
结论:
- 使用FPPA探针的19F-NMR光谱是一种可行的,强大的替代方法,用于A2AAR连接体的发现.
- 这种方法促进了候选药物的选,并扩大了潜在的A2AAR向治疗方法的库.
- 这种方法对发现具有新型核心结构的配体具有前景.
更多相关视频
相关概念视频
Adrenergic Receptors: ɑ Subtype
1.6K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.6K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
892
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
892
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
783
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
783
Adrenergic Agonists: Therapeutic Uses
858
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
858
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
934
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
934
Adrenergic Receptors: β Subtype
1.8K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.8K


